Beth Taylor's Net Worth
$2.4 Million
Who is Beth Taylor?
Beth Taylor has an estimated net worth of $2.4 Million. This is based on reported shares across multiple companies, which include Inotiv, Inc., and ENDOCYTE INC.
SEC CIK
Beth Taylor's CIK is 0001522046
Past Insider Trading and Trends
2018 was Beth Taylor's most active year for acquiring shares with 8 total transactions. Beth Taylor's most active month to acquire stocks was the month of January. 2018 was Beth Taylor's most active year for disposing of shares, totalling 28 transactions. Beth Taylor's most active month to dispose stocks was the month of November. 2022 saw Beth Taylor paying a total of $115,357.50 for 45,000 shares, this is the most they've acquired in one year. In 2018 Beth Taylor cashed out on 271,752 shares for a total of $4,497,363.90, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Inotiv, Inc. (NOTV) Snapshot price: $1.4
Chief Financial OfficerBeth Taylor owns 83,875 units of Common Shares which is worth $117,425.00 and 114,792 units of Common Stock which is worth $160,708.80. From 2020 to 2024 Beth Taylor acquired a total of 114,792 shares in Inotiv, Inc. at a cost of $312,614.38.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +21.10% | 20K |
—
|
—
| 114.79K |
Aug 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 15
| |||
Form 4
| +5.57% | 5K |
—
|
—
| 94.79K |
Feb 17
| |||
Form 4
| +7.05% | 5.92K |
—
|
—
| 89.79K |
Jan 18
| |||
Form 4
| +6.34% | 5K |
$23.07 | $115,357.50 | 83.88K |
Feb 18
| |||
Form 4
| +102.89% | 40K |
—
|
—
| 78.88K |
Feb 15
| |||
Form 4
| +0.55% | 214 |
—
|
—
| 38.88K |
Dec 17
| |||
Form 4
| +3.57% | 1.33K |
—
|
—
| 38.66K |
Oct 22
| |||
Form 4
| +6.12% | 2.15K |
$23.14 | $49,843.56 | 37.33K |
May 13
| |||
Form 4
| +2.57% | 880 |
—
|
—
| 35.17K |
May 7
| |||
Form 4
| +17.07% | 5K |
$17.70 | $88,500.00 | 34.3K |
Mar 5
| |||
Form 4
| +25.73% | 6K |
—
|
—
| 29.3K |
Dec 2
| |||
Form 4
| +75.19% | 10K |
—
|
—
| 23.3K |
Jun 10
| |||
Form 4
|
∞
| 13.3K |
$4.43 | $58,913.32 | 13.3K |
May 19 - May 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ENDOCYTE INC No price found
VP Finance & Chief Acctg OffBeth Taylor used to own units in Common Stock but no longer holds any shares there. In the year 2011 Beth Taylor acquired a total of 118,779 shares in ENDOCYTE INC at a cost of $210,508.66, Beth also disposed a total of 123,687 shares of ENDOCYTE INC equalling to $2,641,754.01.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -99.51K |
$24.00 | -$2,388,216.00 |
0
|
Dec 21
| |||
Form 4
| +76.62% | 43.17K |
$4.31 | $210,508.66 | 99.51K |
Dec 17 - Dec 19
| |||
Form 4
| -11.08% | -7.02K |
$15.56 | -$109,286.90 | 56.34K |
Scheduled
|
Oct 5
| ||
Form 4
| -11.08% | -7.89K |
$20.00 | -$157,840.00 | 63.36K |
Scheduled
|
Aug 28
| ||
Form 4
| -0.40% | -285.00 |
$18.20 | -$5,187.03 | 71.25K |
Scheduled
|
Aug 20
| ||
Form 4
| +20.19% | 12.02K |
$3.00 | -$1,452.00 | 71.54K |
Feb 6 - Feb 8
| |||
Form 4
| -2.87% | -1.76K |
$3.12 | -$5,488.08 | 59.52K |
Feb 2 - Feb 4
| |||
Form 4
| +95.90% | 30K |
—
|
—
| 61.28K |
Oct 4
| |||
Form 4
| +46.99% | 10K |
—
|
—
| 31.28K |
Feb 2
| |||
Form 4
| +21.39% | 3.75K |
—
|
—
| 21.28K |
Aug 18
| |||
Form 4
| +24.33% | 3.23K |
$3.02 | -$1,585.50 | 16.48K |
Feb 4 - Feb 6
| |||
Form 4
| +51.95% | 3.98K |
$5.14 | -$2,698.50 | 11.63K |
Feb 4 - Feb 6
| |||
Form 4
| +315.04% | 5.42K |
—
|
—
| 7.15K |
Feb 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 19
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 29
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||